Cristin-resultat-ID: 1429247
Sist endret: 24. januar 2017 08:59
NVI-rapporteringsår: 2016
Resultat
Vitenskapelig artikkel
2016

Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study

Bidragsytere:
  • Håvard Midgard
  • Jørgen Gustav Bramness
  • Svetlana Skurtveit
  • John Willy Haukeland og
  • Olav Dalgard

Tidsskrift

PLOS ONE
ISSN 1932-6203
e-ISSN 1932-6203
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2016
Volum: 11
Hefte: 11
Artikkelnummer: e0166451
Open Access

Importkilder

Scopus-ID: 2-s2.0-84995470014

Beskrivelse Beskrivelse

Tittel

Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study

Sammendrag

Background and Aims There is limited data on hepatitis C (HCV) treatment uptake among people who inject drugs including individuals receiving opioid substitution treatment (OST). We aimed to calculate cumulative HCV treatment uptake, estimate annual treatment rates, and identify factors associated with HCV treatment among individuals who have received OST in Norway. Methods This observational study was based on linked data from The Norwegian Prescription Database and The Norwegian Surveillance System for Communicable Diseases between 2004 and 2013. Both registries have national coverage. From a total of 9919 individuals who had been dispensed OST (methadone, buprenorphine or buprenorphine-naloxone), we included 3755 individuals who had been notified with HCV infection. In this population, dispensions of HCV treatment (pegylated interferon and ribavirin), benzodiazepines, selective serotonin reuptake inhibitors and antipsychotics were studied. Results Among 3755 OST patients notified with HCV infection, 539 (14%) had received HCV treatment during the study period. Annual HCV treatment rates during OST ranged between 1.3% (95% confidence interval [CI] 0.7-2.2) in 2005 and 2.6% (95% CI 1.9-3.5) in 2008 with no significant changes over time. HCV treatment uptake was not associated with age or gender, but associated with duration of active OST (adjusted odds ratio [aOR] 1.11 per year; 95% CI 1.07-1.15), high (> 80%) OST continuity (aOR 1.62; 95% CI 1.17-2.25), and heavy benzodiazepine use (aOR 0.65; 95% CI 0.49-0.87). Conclusions Cumulative HCV treatment uptake among OST patients notified with HCV infection in Norway between 2004 and 2013 was 14%. Annual treatment rates during OST remained unchanged below 3% per year. High continuity of OST over time and absence of heavy benzodiazepine use predicted HCV treatment uptake. Increased awareness for HCV among OST patients is needed as tolerable and efficient directly acting antiviral treatment is being introduced.

Bidragsytere

Håvard Midgard

  • Tilknyttet:
    Forfatter
    ved Klinikk for indremedisin og laboratoriefag ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Infeksjonsmedisinsk avdeling ved Akershus universitetssykehus HF

Jørgen Gustav Bramness

  • Tilknyttet:
    Forfatter
    ved Senter for rus- og avhengighetsforskning ved Universitetet i Oslo

Svetlana Skurtveit

  • Tilknyttet:
    Forfatter
    ved Avdeling for psykiske lidelser ved Folkehelseinstituttet
  • Tilknyttet:
    Forfatter
    ved Senter for rus- og avhengighetsforskning ved Universitetet i Oslo

John Willy Haukeland

  • Tilknyttet:
    Forfatter
    ved Gastromedisinsk avdeling ved Oslo universitetssykehus HF

Olav Dalgard

  • Tilknyttet:
    Forfatter
    ved Klinikk for indremedisin og laboratoriefag ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Infeksjonsmedisinsk avdeling ved Akershus universitetssykehus HF
1 - 5 av 5